DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. The Company has the exclusive United States marketing rights to its Soltamox (oral liquid tamoxifen). As of December 31, 2011, the Company continues to have an internal clinical development program for its two drug candidates, which cleared investigational new drug applications from the Food and Drug Administration (FDA), KRN5500 and DB959. Its KRN5500 is a non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer. DB959 is a drug candidate for the treatment of type II diabetes and dyslipidemia. On January 17, 2012, the Company acquired Oncogenerix, Inc.